Contrast Media Injectors

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in tissues.

Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Gadopiclenol Injection, a new, highly stable macrocyclic gadolinium-based contrast agent (GBCA), in partnership with Guerbet.. 
News | Contrast Media
Bracco and Guerbet Partner to Expand Access to Novel Imaging Agent

Editor’s note: On September 21, 2022, both Guerbet and Bracco Diagnostics released news detailing the FDA approval of a ...

Time September 22, 2022
arrow
EHR screenshot showing sidebar text displayed to referring clinicians after placing orders for body CT (neck, chest, or abdomen and pelvis), describing iohexol shortage and providing appropriate strategies for iodinated contrast media conservation.
News | Contrast Media
EHR Interventions for Contrast Media Shortage Impact CT Utilization

August 3, 2022 — According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), electronic health ...

Time August 03, 2022
arrow
Bracco Diagnostics has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron® (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage.
News | Contrast Media
FDA Grants Import Discretion of Bracco’s Iodinated Contrast Medium Iomeron (iomeprol injection) to Address Supply Shortages

August 2, 2022 – A new update has been announced as the radiology world continues to address supply disruptions of ...

Time August 02, 2022
arrow
Iodixanol Injection, USP is the first U.S. FDA-approved generic iso-osmolar, dimeric iodinated contrast media agent, which is used during diagnostic x-ray-based imaging such as computed tomography (CT) scans
News | Contrast Media
Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

July 18, 2022 — Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the ...

Time July 18, 2022
arrow
The global contrast media market is projected to reach $5.9 billion by 2026 from $4.9 billion in 2021, at a CAGR of 3.7% during the forecast period.
Feature | Contrast Media
Contrast Media/Contrast Agent Market

The global contrast media market is projected to reach $5.9 billion by 2026 from $4.9 billion in 2021, at a CAGR of 3.7% ...

Time May 03, 2022
arrow
Lawrence N. Tanenbaum, MD FACR is Vice President/Chief Technology Officer Director of CT, MR, and Advanced Imaging for RadNet with 37+ years experience in the medical field. He is a member of editorial boards of several journals/educational organizations and reviewer for scientific journals. He has authored 100+ scholarly and peer-reviewed articles, chairs educational/academic meetings, and has delivered 2000+ invited global lectures.
Sponsored Content | Case Study | Contrast Media Injectors
Case Studies with Lawrence N. Tanenbaum, MD FACR Using Macrocyclic CLARISCAN (gadoterate meglumine) Injection for Intravenous Use

Product Indications and Use: CLARISCAN (gadoterate meglumine) is a gadolinium-based contrast agent indicated for ...

Time May 03, 2022
arrow
NEXO[DOSE] dashboard
Sponsored Content | Blog | Radiation Dose Management
Effective Radiation Dose Management Improves Imaging Practices, Patient Safety and Ensures Compliance

Early-stage detection is key to the prevention of life-threatening diseases; however, limited access to data hinders the ...

Time April 11, 2022
arrow
EmpowerMR Injector System
Sponsored Content | Blog | Contrast Media Injectors
BLOG: Advanced Injector System Provides Greater Control and Accelerates Patient Care

Medical imaging and contrast use have become an integral part of the diagnostic process to determine the best ...

Time February 28, 2022
arrow
Sponsored Content | Blog | Contrast Media Injectors
BLOG: Patient-centric Injector Solutions Help CT Departments Take Control, Improve Safety

Patient safety is a fundamental requirement to all applications of radiology techniques and procedures. As the ...

Time January 21, 2022
arrow
In February 2021, Guerbet announced the launch of OptiProtect 3S (Smart Service Solutions), a range of technical services for its injection solutions. OptiProtect 3S is designed to support imaging centers in the daily use and protection of their injection solutions.
Feature | Contrast Media Injectors | By Melinda Taschetta-Millane
Contrast Media Injectors Market Outlook

Contrast media injectors are used to inject contrast agents to enhance the blood and perfusion in tissues. There have ...

Time January 19, 2022
arrow
The global contrast media market size is expected to reach USD 7.2 billion by 2028 and is expected to expand at a CAGR of 8.6% from 2021 to 2028.
News | Contrast Media
Global Contrast Media Trends and Analysis Report 2021

December 30, 2021 — The "Global Contrast Media Market Size, Share & Trends Analysis Report by Product Type (Iodinated ...

Time December 30, 2021
arrow
Qaelum NV announced that they enter into a strategic partnership with ulrich GmbH & Co. KG in Ulm to combine their advanced Contrast Management solution with the contrast media injectors of ulrich medical, to support the needs of hospitals and imaging networks.
News | Contrast Media Injectors
Qaelum NV and ulrich Medical Enter Into a Strategic Partnership

December 13, 2021 — Qaelum NV announced that they enter into a strategic partnership with ulrich GmbH & Co. KG in Ulm to ...

Time December 13, 2021
arrow
Avoiding contrast dyes for imaging tests not necessary if concerned about iodine allergy, peer-reviewed study concludes #MRI
News | Contrast Media Injectors
New Research Shatters Age-old Iodine Allergy Myth

September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthcare ...

Time September 16, 2021
arrow
Sponsored Content | Blog | Contrast Media Injectors
BLOG: Smart Injector Technology Delivers Effective and Efficient Patient Care

Technology advancements are changing consumers’ expectations, driving industries to adapt and evolve, and the healthcare ...

Time April 29, 2021
arrow
The contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence and prevalence of chronic diseases and demand for diagnostic and interventional radiology procedures, increase in aging population, expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement
News | Contrast Media
Contrast Media Agents Global Market

Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or ...

Time May 03, 2021
arrow
Guerbet announced the launch of OptiProtect 3S, a new range of technical services for its injection solutions. OptiProtect 3S is designed to support imaging centers in the daily use and protection of their injection solutions.
News | Contrast Media Injectors
Guerbet Launches OptiProtect 3S

February 25, 2021 — Guerbet announced the launch of OptiProtect 3S, a new range of technical services for its injection ...

Time February 25, 2021
arrow
Steinberg Diagnostic Medical Imaging headquarters.
Sponsored Content | Case Study | Contrast Media Injectors
Steinberg Diagnostic Medical Imaging

Steinberg Diagnostic Medical Imaging (SDMI) was founded 30 years ago and has grown to be one of the largest outpatient ...

Time January 21, 2021
arrow
According to a new research report1 on the contrast media injectors published by MarketsandMarkets, the market was estimated to be $1.3 billion in 2020 and projected to reach $1.9 billion by 2025, at a compound annual growth rate (CAGR) of 7.4 percent over 2020-2025.
Feature | Contrast Media Injectors | By Melinda Taschetta-Millane
2021 Outlook for the Contrast Media Injectors Market

According to a new research report1 on the contrast media injectors published by MarketsandMarkets, the market was ...

Time January 20, 2021
arrow
This novel agent, based on the essential nutrient manganese, has strong potential as a safer alternative to currently used contrast agents
News | Contrast Media
Novel MRI Contrast Agent Sidesteps Toxic Effects of Current Products

December 28, 2020 — Adding a contrast-enhancing agent to magnetic resonance imaging (MRI) significantly improves image ...

Time December 28, 2020
arrow
GE Healthcare has received U.S. FDA approval of its macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine), in pre-filled syringes. #RSNA20
News | Contrast Media
GE Healthcare Announces U.S. FDA approval of macrocyclic MRI Contrast Agent Clariscan in Pre-Filled Syringes

November 26, 2020 — GE Healthcare has received U.S. FDA approval of its macrocyclic gadolinium-based MRI contrast agent ...

Time November 26, 2020
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now